Please login to the form below

Not currently logged in
Email:
Password:

Dovato

This page shows the latest Dovato news and features for those working in and with pharma, biotech and healthcare.

GSK considers more divestments to help R&D push

GSK considers more divestments to help R&D push

There was an acceleration in sales of ViiV’s new two-drug combinations Juluca (dolutegravir/rilpivirine) and Dovato (dolutegravir/lamivudine) however, which GSK sees as the main weapon in its arsenal

Latest news

  • ViiV builds case for switching to its two-drug HIV combinations ViiV builds case for switching to its two-drug HIV combinations

    48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing ... ViiV – which is majority owned by

  • ViiV bags EU okay for new two-drug HIV therapy ViiV bags EU okay for new two-drug HIV therapy

    Rivals Gilead's Biktarvy. ViiV Healthcare now has approval on both sides of the Atlantic for two-drug HIV therapy Dovato after a green light from the EMA. ... Dovato – a fixed-dose combination of ViiV’s blockbuster integrase inhibitor Tivicay

  • Shingrix lifts GSK in Q1, but two more vaccines are culled Shingrix lifts GSK in Q1, but two more vaccines are culled

    All eyes now are on Dovato (dolutegravir/lamivudine), GSK’s new two-drug combination that was recently the first ever once-a-day two-drug regimen to be approved for treating ... ViiV chairman David Redfern said Juluca and Dovato – alongside GSK’s

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... Meanwhile, Dovato (dolutegravir/lamivudine) developed by GSK-led

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    Dovato (dolutegravir/lamivudine) is marketed by GSK-led joint venture ViiV, and is the first ever once-a-day two-drug STR for treating treatment-naïve patients. ... seen whether or not the same will be true for 2-drug STRs such as Dovato.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...